Perinatal Transient Myeloproliferative Disorder in Trisomy 21
Transient myeloproliferative disorder (TMD), also known as transient acute myelopoiesis, is a myeloproliferative condition that occurs in the perinatal period in up to 10% of patients who have Down syndrome. Because of the perinatal presentation of this disorder, neonatal clinicians should be familiar with its clinical presentation, management, and outcomes. Affected patients develop severe myeloproliferation of megakaryocytic precursor cells, leading initially to hepatosplenomegaly and liver dysfunction. If the disorder develops prenatally, affected fetuses may also develop hydrops. The disorder requires the presence of 2...
Source: NeoReviews recent issues - October 31, 2016 Category: Pediatrics Authors: OConnell, A. E., Mulla, B. M., OBrien, K., Yoon, E. J., Carterson, A., Brodsky, D. Tags: Pediatric Drug Labeling Update Articles Source Type: news
Update on the Management of Myeloproliferative Neoplasms
In this interview we discuss symptoms and prognosis for patients with polycythemia vera and essential thrombocythemia and the treatment of myelofibrosis. (Source: CancerNetwork)
Source: CancerNetwork - September 30, 2016 Category: Cancer & Oncology Authors: Ruben A. Mesa, MD Tags: Hematologic Malignancies Conferences/NCCN 2016 Source Type: news
Learning units launched to mark leukaemia day
Nursing Times has today launched new online education resources on haematological cancers known as myeloproliferative neoplasms to coincide with International Chronic Myeloid Leukaemia Day. (Source: Nursing Times)
Source: Nursing Times - September 22, 2016 Category: Nursing Source Type: news
The 3rd Annual US Focus on Myeloproliferative Neoplasms and...
Expert review and analysis of the latest scientific advances in MPN and MDS(PRWeb August 16, 2016)Read the full story at http://www.prweb.com/releases/2016/08/prweb13615206.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 16, 2016 Category: Pharmaceuticals Source Type: news
Summary Information for: PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD)
Labeling, Approval Order, and Summary of Safety and Effectiveness for PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD) (H140005). (Source: Food and Drug Adminstration (FDA): CDRHNew)
Source: Food and Drug Adminstration (FDA): CDRHNew - January 14, 2016 Category: Medical Equipment Source Type: news
Detection and Genotyping of CALR Mutations in Myeloproliferative NeoplasmsDetection and Genotyping of CALR Mutations in Myeloproliferative Neoplasms
The authors developed a PCR-based approach to detect CALR mutations in myeloproliferative neoplasms, which can reduce labor and improve turnaround time in the clinical lab. American Journal of Clinical Pathology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - December 18, 2015 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news
Drug Active in Myeloproliferative Disorders (CME/CE)
(MedPage Today) -- Essential thrombocythemia, myelofibrosis respond to telomere targeting (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 2, 2015 Category: Hematology Source Type: news
MPN Research Foundation Encourages People to Use Social Media During...
During September as part of Blood Cancer Awareness Month, MPN Research Foundation asks people to raise awareness for myeloproliferative neoplasms by changing their Facebook profile picture(PRWeb August 28, 2015)Read the full story at http://www.prweb.com/releases/2015/08/prweb12926272.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 28, 2015 Category: Pharmaceuticals Source Type: news
AOP Orphan Pharmaceuticals announces progress of Phase III Trial PROUD-PV
Ropeginterferon alfa 2b is a novel, long-acting, mono-pegylated Interferon, administered only once every 14 days, after achieving therapy response even only monthly.
Based on previous Phase I/II trials, Ropeginterferon alfa 2b is expected to be safe and effective in the majority of PV patients.
Haematological and molecular responses occured in most patients; moreover, several patients achieved undetectable mutated JAK2 levels and a complete normalisation of their chromosomal make-up. (Source: Pharmacy Europe)
Source: Pharmacy Europe - March 10, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Haematology Oncology Patient care JAK2 Latest News myeloproliferative neoplasms Polycythemia Vera PROUD-PV Ropeginterferon alfa 2b Source Type: news
Myelodysplastic Syndromes / Myeloproliferative Disorders
What are myelodysplastic syndromes?Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterized by ineffective hemopoiesis leading to blood cytopenias, and by progression to acute myeloid leukemia in a third of patients. Who is affected?15% of cases occur after chemotherapy or radiotherapy for a previous cancer. The syndromes are most common in elderly people. What is the cause?The pathophysiology involves cytogenetic changes with or without gene mutations and widespread gene hypermethylation at advanced stages. What are the symptoms?Clinical manifestations result from cytopenias (anemia, infection, and b...
Source: Clinical Cases and Images - March 3, 2015 Category: Journals (General) Tags: Hematology Mayo Clinic Oncology Video Source Type: news
How Common is Gout?
Discussion
Purines are heterocyclic aromatic organic compounds. Common ones are adenine, guanine, xanthine, hypoxanthine, uric acid and caffeine. The most common sources of purines are meat (especially liver, kidney, and brain), certain fish (herring, mackerel, anchovies, sardines), and in lower amounts in beans, and certain plants and yeast. Purines are synthesized, used by the body, then they are degraded by a variety of enzymes. They then can be salvaged to resynthesize purines or are eliminated primarily by the kidney.
When intake or synthesis outweighs elimination then hyperuricemia can result. Hyperuricemia can occu...
Source: PediatricEducation.org - February 16, 2015 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
MPN Research Foundation initiates exploratory gene editing project
CRISPR technology to be evaluated for its applicability and safety for blood cancer group myeloproliferative neoplasms.(PRWeb February 12, 2015)Read the full story at http://www.prweb.com/releases/2015/02/prweb12506359.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 14, 2015 Category: Pharmaceuticals Source Type: news
Department of Defense Doubles Cancer Research Funding in 2015
Doctors and researchers seeking a cure for mesothelioma will soon be able to tap into millions of dollars set aside by the U.S. Department of Defense for cancer research.
The Office of Congressionally Directed Medical Research Programs (CDMRP) invested $50 million in the Peer Reviewed Cancer Research Program (PRCRP) for 2015 — an amount that doubles the money awarded to the program last year.
With the additional funding, asbestos-related cancer researchers can extend current studies and launch new ones to improve traditional treatments, introduce emerging therapies or test new cancer drugs. Funding in 2014 was $25 milli...
Source: Asbestos and Mesothelioma News - February 5, 2015 Category: Environmental Health Authors: Walter Pacheco Tags: Research & Clinical Trials Source Type: news
FASEB Science Research Conference: Hematologic Malignancies
(Federation of American Societies for Experimental Biology) This FASEB Science Research Conference has a long pedigree as one of the premier meetings for fundamental and translational research in the hematologic malignancies including acute and chronic leukemia, the myeloproliferative neoplasms, myelodysplastic syndromes, myeloma and lymphoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 22, 2015 Category: Global & Universal Source Type: news
Galena completes patient enrolment in Phase II GALE-401 trial
Galena Biopharma has completed patient enrolment in the GALE-401, or Anagrelide Controlled Release, Phase II clinical trial to treat patients with elevated platelet counts in myeloproliferative neoplasms (MPNs) including essential thrombocythemia (ET… (Source: Drug Development Technology)
Source: Drug Development Technology - November 20, 2014 Category: Pharmaceuticals Source Type: news
